Article

Weight Loss Could Lead to Decreased Expression of Cancer-Promoting Proteins

Participants who lost weight showed decreased expression of proteins that promote tumor-related angiogenesis.

Overweight or obese women who lost weight through diet and exercise also lowered the level of 3 proteins in the blood that promote tumor growth.

In a study published by Cancer Research, investigators measured the amount of 3 proteins known to increase tumor-related angiogenesis in the blood of 439 postmenopausal women.

Researchers analyzed how the expression of the proteins changed once the overweight, sedentary participants lost weight through diet and/or exercise.

Patients either went on a calorie- and fat-restricted diet, participated in aerobic exercise 5 days per week, combined diet and exercise, or participated in no interventions. The researchers found that participants in the diet group and the diet with exercise group lost the most weight, and had lower levels of angiogenesis-related proteins compared with women in the exercise group, or the control group, according to the study.

These findings suggest that weight loss could be an effective way to improve the “angiogenic profile” of individuals. The researchers concluded that there could be a link between reduced levels of the proteins and decreased tumor growth.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com